Published in Eur J Cancer on November 28, 1995
Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: evidence for the involvement of RNA perturbation. Proc Natl Acad Sci U S A (1997) 1.73
Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. Br J Cancer (1997) 1.05
From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates. Invest New Drugs (2006) 0.97
New developments in cancer treatment with the novel thymidylate synthase inhibitor raltitrexed ('Tomudex'). Br J Cancer (1998) 0.80
Structure of the Varicella Zoster Virus Thymidylate Synthase Establishes Functional and Structural Similarities as the Human Enzyme and Potentiates Itself as a Target of Brivudine. PLoS One (2015) 0.77
Involvement of bcl-2 and p21waf1 proteins in response of human breast cancer cell clones to Tomudex. Br J Cancer (1999) 0.77
Population pharmacokinetics of raltitrexed in patients with advanced solid tumours. Br J Clin Pharmacol (2004) 0.75
The renal effects of the water-soluble, non-folylpolyglutamate synthetase-dependent thymidylate synthase inhibitor ZD9331 in mice. Br J Cancer (1998) 0.75
Phase I study of Tomudex and Doxorubicin in patients with locally advanced, inoperable or metastatic cancer (IND.98). Invest New Drugs (2005) 0.75
A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies. Invest New Drugs (2004) 0.75
Proteins specified by herpes simplex virus. 8. Characterization and composition of multiple capsid forms of subtypes 1 and 2. J Virol (1972) 11.71
Identification and characterization of multiple forms of actin. Cell (1976) 5.87
Proteins specified by herpes simplex virus. Staining and radiolabeling properties of B capsid and virion proteins in polyacrylamide gels. J Virol (1974) 5.74
Paradoxical activation of Raf by a novel Raf inhibitor. Chem Biol (1999) 4.98
Polyoma virus proteins: a description of the structural proteins of the virion based on polyacrylamide gel electrophoresis and peptide analysis. Virology (1974) 3.74
Isolation and characterization of a noninfectious virion-like particle released from cells infected with human strains of cytomegalovirus. Virology (1983) 3.32
Structural and nonstructural proteins of strain Colburn cytomegalovirus. Virology (1981) 2.91
Protein counterparts of human and simian cytomegaloviruses. Virology (1983) 2.80
Studies on the reverse transcriptase of RNA tumor viruses. Structural relatedness of two subunits of avian RNA tumor viruses. Proc Natl Acad Sci U S A (1974) 2.60
A herpesvirus maturational proteinase, assemblin: identification of its gene, putative active site domain, and cleavage site. Proc Natl Acad Sci U S A (1991) 2.50
Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol (1982) 2.50
Tumour volume response, initial cell kill and cellular repopulation in B16 melanoma treated with cyclophosphamide and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea. Br J Cancer (1977) 2.31
Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med (1990) 2.15
Identification of the lytic origin of DNA replication in human cytomegalovirus by a novel approach utilizing ganciclovir-induced chain termination. J Virol (1990) 2.10
Characterization of phosphoproteins and protein kinase activity of virions, noninfectious enveloped particles, and dense bodies of human cytomegalovirus. J Virol (1986) 2.09
UKCCCR guidelines for the welfare of animals in experimental neoplasia. Lab Anim (1988) 1.95
ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res (1991) 1.94
Primate cytomegalovirus assembly: evidence that DNA packaging occurs subsequent to B capsid assembly. Virology (1988) 1.91
Compartmentalization of spermine and spermidine in the herpes simplex virion. Proc Natl Acad Sci U S A (1971) 1.88
Cytomegalovirus assembly protein nested gene family: four 3'-coterminal transcripts encode four in-frame, overlapping proteins. J Virol (1991) 1.82
Laryngeal abductor paralysis in multiple system atrophy. A report on three necropsied cases, with observations on the laryngeal muscles and the nuclei ambigui. Brain (1981) 1.80
Identification of the human cytomegalovirus G protein-coupled receptor homologue encoded by UL33 in infected cells and enveloped virus particles. Virology (1996) 1.80
Capsid structure of simian cytomegalovirus from cryoelectron microscopy: evidence for tegument attachment sites. J Virol (1999) 1.79
Repopulation of gamma-irradiated Lewis lung carcinoma by malignant cells and host macrophage progenitors. Br J Cancer (1978) 1.77
Characterization of the major polypeptides of the rat liver nuclear envelope. J Biol Chem (1983) 1.75
The Drosophila suppressor of sable gene encodes a polypeptide with regions similar to those of RNA-binding proteins. Mol Cell Biol (1991) 1.71
A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer (1996) 1.67
Immediate-early proteins of human cytomegalovirus strains AD 169, Davis, and Towne differ in electrophoretic mobility. Virology (1981) 1.61
beta-D-glucosyl-hydroxymethyluracil is a conserved DNA modification in kinetoplastid protozoans and is abundant in their telomeres. Proc Natl Acad Sci U S A (1998) 1.60
Primate cytomegalovirus assembly protein: genome location and nucleotide sequence. J Virol (1989) 1.58
Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. Br J Cancer (1989) 1.56
The molecular evolution of trypanosomes. Parasitol Today (1999) 1.55
Human cytomegalovirus capsid assembly protein precursor (pUL80.5) interacts with itself and with the major capsid protein (pUL86) through two different domains. J Virol (1997) 1.52
Cell survival in B16 melanoma after treatment with combinations of cytotoxic agents: lack of potentiation. Br J Cancer (1977) 1.51
Do patients with left circumflex coronary artery-related acute myocardial infarction without ST-segment elevation benefit from reperfusion therapy? Am J Cardiol (1995) 1.47
The 45-kilodalton protein of cytomegalovirus (Colburn) B-capsids is an amino-terminal extension form of the assembly protein. J Virol (1991) 1.46
Cytomegalovirus basic phosphoprotein (pUL32) binds to capsids in vitro through its amino one-third. J Virol (2001) 1.45
Genetic nomenclature for Trypanosoma and Leishmania. Mol Biochem Parasitol (1998) 1.45
Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. J Clin Oncol (1996) 1.44
Microtubule network facilitates nuclear targeting of human cytomegalovirus capsid. J Virol (2003) 1.43
Cytomegalovirus homologs of cellular G protein-coupled receptor genes are transcribed. J Virol (1991) 1.43
A cycloheximide-enhanced protein in cytomegalovirus-infected cells. Virology (1980) 1.43
Characterization of the mRNA's for the polyoma virus capsid proteins VP1, VP2, and VP3. J Virol (1978) 1.43
Virion basic phosphoprotein from human cytomegalovirus contains O-linked N-acetylglucosamine. Proc Natl Acad Sci U S A (1988) 1.42
The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br J Cancer (1991) 1.42
Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug. Cancer Res (1993) 1.42
Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates. Cancer Res (1992) 1.37
Congenital insensitivity to pain with anhidrosis: novel mutations in the TRKA (NTRK1) gene encoding a high-affinity receptor for nerve growth factor. Am J Hum Genet (1999) 1.36
A potent antitumour quinazoline inhibitor of thymidylate synthetase: synthesis, biological properties and therapeutic results in mice. Eur J Cancer (1981) 1.35
Sequence requirements for proteolytic processing of glycoprotein B of human cytomegalovirus strain Towne. J Virol (1990) 1.33
The molecular evolution of Trypanosomatidae. Adv Parasitol (2001) 1.33
The selectivity of action of alkylating agents and drug resistance. I. Biochemical changes occurring in sensitive and resistant strains of the Yoshida ascites sarcoma following chemotherapy. Br J Cancer (1969) 1.30
Cell yield and cell survival following chemotherapy of the B16 melanoma. Br J Cancer (1978) 1.30
Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function. Cancer Res (1984) 1.29
Collagenolytic activity in gingivae of man. Nature (1966) 1.28
Enhanced cell killing in lewis lung carcinoma and a human pancreatic-carcinoma xenograft by the combination of cytotoxic drugs and misonidazole. Br J Cancer (1981) 1.23
The selectivity of action of alkylating agents and drug resistance. 3. The uptake and degradation of alkylating drugs by Yoshida ascites sarcoma cells in vitro. Biochem Pharmacol (1970) 1.22
Site-specific glycosylation of the human cytomegalovirus tegument basic phosphoprotein (UL32) at serine 921 and serine 952. J Virol (1994) 1.22
Flameless atomic absorption spectrophotometric determination of platinum in tissues solubilized in hyamine hydroxide. Anal Biochem (1987) 1.22
Ammine/amine platinum(IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res (1992) 1.21
Adenosine deaminase activity in leukaemia. Br J Cancer (1975) 1.19
Preclinical studies identifying carboplatin as a viable cisplatin alternative. Cancer Treat Rev (1985) 1.15
Primate cytomegalovirus glycoproteins: lectin-binding properties and sensitivities to glycosidases. J Virol (1986) 1.15
Identification and characterization of a major early cytomegalovirus DNA-binding protein. J Virol (1986) 1.14
Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. J Med Chem (2000) 1.13
The application of 5,5' dithiobis-2-nitrobenzoic acid to the determination of the acid-soluble disulphide content of blood. Biochem Pharmacol (1967) 1.12
Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines. Br J Cancer (1995) 1.12
Altered virion proteins of a temperature-sensitive mutant of polyoma virus, ts59. Virology (1977) 1.11
Phase I studies with carboplatin at the Royal Marsden Hospital. Cancer Treat Rev (1985) 1.11
Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line. Cancer Res (1992) 1.10
Cytomegalovirus-infected cells contain a DNA-binding protein. Virology (1981) 1.10
Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors. J Clin Oncol (1996) 1.10
Waterpipe tobacco and cigarette smoking among university students in Jordan. Int J Tuberc Lung Dis (2012) 1.10
A modular and optimized single marker system for generating Trypanosoma brucei cell lines expressing T7 RNA polymerase and the tetracycline repressor. Open Biol (2012) 1.10
Folate-based thymidylate synthase inhibitors as anticancer drugs. Ann Oncol (1995) 1.09
Identification of Trypanosoma brucei gambiense by PCR amplification of variant surface glycoprotein genes. Acta Trop (1993) 1.09
Dose-rate effects and the repair of radiation damage. Radiother Oncol (1986) 1.09
Influence of anaesthetics on tumour-cell kill and repopulation in B16 melanoma treated with melphalan. Br J Cancer (1978) 1.09
Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes. Br J Cancer (1992) 1.08
Methotrexate toxicity: correlation with duration of administration, plasma levels, dose and excretion pattern. Eur J Cancer (1972) 1.07
cis-Diamminedichloroplatinum(II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol (1996) 1.07
Intrinsic resistance to methotrexate of cultured mammalian cells in relation to the inhibition kinetics of their dihydrololate reductases. Cancer Res (1976) 1.06
Cisplatin induces apoptosis in a human ovarian carcinoma cell line without concomitant internucleosomal degradation of DNA. Exp Cell Res (1994) 1.06
The role of the reduced-folate carrier and metabolism to intracellular polyglutamates for the activity of ICI D1694. Adv Exp Med Biol (1993) 1.05
Comparison between African-American and white women in their beliefs about breast cancer and their health locus of control. Cancer Nurs (2000) 1.05
Mobile element insertions causing mutations in the Drosophila suppressor of sable locus occur in DNase I hypersensitive subregions of 5'-transcribed nontranslated sequences. Genetics (1990) 1.04
Selection of particles and proteins for use as human cytomegalovirus subunit vaccines. Birth Defects Orig Artic Ser (1984) 1.03
Effect of environmental temperature on the kinetic properties of goldfish brain choline acetyltransferase. Biochem J (1972) 1.03
Further analysis of intraspecific variation in Trypanosoma brucei using restriction site polymorphisms in the maxi-circle of kinetoplast DNA. Mol Biochem Parasitol (1985) 1.02